Kyverna Therapeutics, Inc. KYTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s cash & equivalents?
- Kyverna Therapeutics, Inc. (KYTX) reported cash & equivalents of $32.19M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Kyverna Therapeutics, Inc.'s cash & equivalents decreased by 43.4% year-over-year, from $56.87M to $32.19M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s cash & equivalents?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s cash & equivalents has grown at a 89.3% compound annual growth rate (CAGR), from $34.65M to $124.09M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.